JP2003511370A - 糖尿病及び老化に関連する血管合併症の治療のための化合物 - Google Patents

糖尿病及び老化に関連する血管合併症の治療のための化合物

Info

Publication number
JP2003511370A
JP2003511370A JP2001528155A JP2001528155A JP2003511370A JP 2003511370 A JP2003511370 A JP 2003511370A JP 2001528155 A JP2001528155 A JP 2001528155A JP 2001528155 A JP2001528155 A JP 2001528155A JP 2003511370 A JP2003511370 A JP 2003511370A
Authority
JP
Japan
Prior art keywords
pyridinium
pharmaceutically acceptable
oxoethyl
acceptable salt
bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001528155A
Other languages
English (en)
Japanese (ja)
Inventor
サンカラナラヤナン、アラングディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Torrent Pharmaceuticals Ltd
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of JP2003511370A publication Critical patent/JP2003511370A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2001528155A 1999-10-06 1999-10-15 糖尿病及び老化に関連する血管合併症の治療のための化合物 Pending JP2003511370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN827CAL99 1999-10-06
IN827CA1999 1999-10-06
PCT/IB1999/001687 WO2001025209A1 (en) 1999-10-06 1999-10-15 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications

Publications (1)

Publication Number Publication Date
JP2003511370A true JP2003511370A (ja) 2003-03-25

Family

ID=11084921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001528155A Pending JP2003511370A (ja) 1999-10-06 1999-10-15 糖尿病及び老化に関連する血管合併症の治療のための化合物

Country Status (12)

Country Link
EP (1) EP1220843A1 (cs)
JP (1) JP2003511370A (cs)
CN (1) CN1329597A (cs)
AU (1) AU5994499A (cs)
BR (1) BR9915962A (cs)
CA (1) CA2351075A1 (cs)
CZ (1) CZ20011808A3 (cs)
HK (1) HK1044336A1 (cs)
HU (1) HUP0301687A2 (cs)
MX (1) MXPA02003496A (cs)
PL (1) PL348049A1 (cs)
WO (1) WO2001025209A1 (cs)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155315A (ja) * 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
JP2015535849A (ja) * 2012-10-05 2015-12-17 スファエラ ファーマ ピーティーイー リミテッド 新規化合物、それらの合成及びそれらの使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067851A2 (en) * 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
CZ303214B6 (cs) * 2001-03-21 2012-05-30 Torrent Pharmaceuticals Ltd Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
ES2243389T3 (es) * 2001-03-21 2005-12-01 Torrent Pharmaceuticals Ltd Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age.
AU2002253432B2 (en) 2001-04-05 2005-03-24 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
JP2003137783A (ja) * 2001-10-19 2003-05-14 Torrent Pharmaceuticals Ltd 美容及び治療用途におけるピリジニウム誘導体の使用のための組成物及び方法
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
WO2007132179A2 (en) * 2006-05-15 2007-11-22 University Of Bath Therapeutics comprising pyridinium derivatives
CN102459175A (zh) 2009-05-07 2012-05-16 托蓝特医药公司 用于治疗糖尿病的哌啶衍生物
BR112017021631A2 (pt) * 2015-04-08 2018-07-03 Torrent Pharmaceuticals Limited composto, composição farmacêutica, combinação farmacêutica, método de tratamento, uso de um composto e processo para preparação de dito composto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
US3318787A (en) * 1964-02-07 1967-05-09 Udylite Corp Electrodeposition of zinc
US3823076A (en) * 1972-05-23 1974-07-09 Du Pont Zinc electroplating additive
JPS5936247B2 (ja) * 1977-04-20 1984-09-03 ティーディーケイ株式会社 電気的表示装置
JPS55138742A (en) * 1979-04-17 1980-10-29 Fuji Photo Film Co Ltd Silver halide emulsion developing method
JPH0253759A (ja) * 1988-08-18 1990-02-22 Hamari Yakuhin Kogyo Kk 新規な４級アンモニウム化合物
DD275872A1 (de) * 1988-09-27 1990-02-07 Univ Dresden Tech Verfahren zur herstellung von 5h-pyrido[1',2':1,2]imidazo[5,4-c]chinolin-6-onen
CA2210684C (en) * 1995-01-18 2008-01-15 Alteon Inc. Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts
JP2001519813A (ja) * 1997-04-04 2001-10-23 スミスクライン・ビーチャム・コーポレイション カルシウム溶解性化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009155315A (ja) * 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
JP2015535849A (ja) * 2012-10-05 2015-12-17 スファエラ ファーマ ピーティーイー リミテッド 新規化合物、それらの合成及びそれらの使用

Also Published As

Publication number Publication date
PL348049A1 (en) 2002-05-06
CZ20011808A3 (cs) 2001-08-15
BR9915962A (pt) 2003-01-07
CN1329597A (zh) 2002-01-02
AU5994499A (en) 2001-05-10
HK1044336A1 (zh) 2002-10-18
WO2001025209A1 (en) 2001-04-12
HUP0301687A2 (hu) 2003-08-28
CA2351075A1 (en) 2001-04-12
EP1220843A1 (en) 2002-07-10
MXPA02003496A (es) 2005-06-20

Similar Documents

Publication Publication Date Title
JP6937812B2 (ja) 貧血治療のための組成物及び方法
JP2854631B2 (ja) 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
JP4068843B2 (ja) 老化関連及び糖尿病性血管合併症の管理のためのピリジニウム誘導体、それらの製造方法並びにそれらの治療的使用
JP2003511370A (ja) 糖尿病及び老化に関連する血管合併症の治療のための化合物
JP4837992B2 (ja) 蛋白修飾物生成抑制剤
JPH03161441A (ja) メイラード反応阻害剤
JP4471141B2 (ja) 老化関連及び糖尿病脈管合併症の管理のための新規化合物、その製造方法及び治療的使用
JP5797370B2 (ja) 置換された５員アザシクロの新規塩およびタンパク質老化に関連する疾患の治療におけるその使用
US11180463B2 (en) Thiazole inner salt compounds, and preparation methods and uses thereof
JPH02753A (ja) カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
JP3942740B2 (ja) アミノ酸誘導体・オキソバナジウム（ｉｖ）錯体
JP2002515033A (ja) 置換イミダゾリウム塩、及びタンパク質老化を阻止するためのそれらの使用
WO2021229832A1 (ja) ベネトクラクスの水溶性高分子誘導体
JPWO2005051930A1 (ja) 蛋白修飾物生成抑制剤
JPH0363299A (ja) 修飾エリスロポエチン
CH677610A5 (cs)
JPH02765A (ja) アミノグアニジン誘導体およびそれらを有効成分として含有するメイラード反応阻害剤
JP2003119142A (ja) 糖化蛋白変性物質生成阻害剤
JPH0733661A (ja) 脳疾患予防治療剤
JPH03261772A (ja) チアゾリジン系化合物およびこれを含有するグリケーション阻害剤
JP2002515870A (ja) タンパク質グリコシル化阻害のための１，２，４―トリアジン誘導体

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040309